Promising news for Tourette syndrome research: a Phase III clinical trial led by researchers at Cincinnati Children's found that ecopipam reduced tics and lowered relapse risk in children.
Findings published in JAMA Neurology.
Learn more:
#TouretteSyndrome #Neuroscience #PediatricResearch
Continued use of a drug called ecopipam can cut the risk of relapse in half for children battling tics caused by Tourette syndrome (TS).
